- $67.07m
- $52.77m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -246.26% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Directors
- Duane Nash CHM (50)
- Daniel Vitt PRE (52)
- Glenn Whaley CFO (53)
- Manfred Groppel COO (52)
- Hella Kohlhof CSO (48)
- Inderpal Singh GCN
- Andreas Muehler OTH (57)
- Patrick Walsh OTH
- Tamar Howson IND (73)
- Jorg Neermann IND (54)
- Vincent Ossipow IND (52)
- Barclay Phillips IND (58)
- Jan Van den Bossche IND (43)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 13th, 2004
- Public Since
- April 17th, 2014
- No. of Shareholders
- 29
- No. of Employees
- 91
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 95,817,536
- Address
- 1200 Avenue Of The Americas, Suite 200, NEW YORK, 10036
- Web
- https://imux.com/
- Phone
- +49 89250079460
- Contact
- Jessica Breu
- Auditors
- BAKER TILLY US LLP
Upcoming Events for IMUX
Q3 2025 Immunic Inc Earnings Release
Similar to IMUX
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Immunic share price?
As of Today at 21:14 UTC, shares in Immunic are trading at $0.70. This share price information is delayed by 15 minutes.
How has the Immunic share price performed this year?
Shares in Immunic last closed at $0.70 and the price had moved by -31.37% over the past 365 days. In terms of relative price strength the Immunic share price has underperformed the S&P500 Index by -39.29% over the past year.
What are the analyst and broker recommendations for Immunic?
The overall consensus recommendation for Immunic is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immunic dividend yield?
Immunic does not currently pay a dividend.
Does Immunic pay a dividend?
Immunic does not currently pay a dividend.
When does Immunic next pay dividends?
Immunic does not currently pay a dividend.
How do I buy Immunic shares?
To buy shares in Immunic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immunic?
As of the previous close price of $0.70, shares in Immunic had a market capitalisation of $67.07m.
Where are Immunic shares listed?
Here are the trading details for Immunic:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: IMUX
What kind of share is Immunic?
Based on an overall assessment of its quality, value and momentum Immunic is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immunic share price forecast for 2025?
The analyst consensus target price for shares in Immunic is $11.17. That is 1495.71% above the last closing price of $0.70.
Analysts covering Immunic currently have a consensus Earnings Per Share (EPS) forecast of -$0.68 for the next financial year.
Find out moreWhat is the trend in the Immunic share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immunic. Over the past six months, its share price has underperformed the S&P500 Index by -34.97%.
As of the last closing price of $0.70, shares in Immunic were trading -37.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immunic PE Ratio?
The Immunic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immunic?
Immunic's management team is headed by:
- Duane Nash - CHM
- Daniel Vitt - PRE
- Glenn Whaley - CFO
- Manfred Groppel - COO
- Hella Kohlhof - CSO
- Inderpal Singh - GCN
- Andreas Muehler - OTH
- Patrick Walsh - OTH
- Tamar Howson - IND
- Jorg Neermann - IND
- Vincent Ossipow - IND
- Barclay Phillips - IND
- Jan Van den Bossche - IND